BUSINESS MODEL
We build the technology once. We licence it to our partners.
Alvion Bio is a biotech platform company, not a drug developer. We do not run clinical trials, hold regulatory approvals, or bear the risk of bringing medicines to market. We build and own the foundational cell technology that makes those medicines possible, and we earn from it every time a partner uses it.
One platform. Multiple partners. Compounding revenue.
What kind of company is Alvion Bio?
The ingredient supplier to the cell therapy industry.
The pharmaceutical industry has two kinds of companies. There are developers, organisations that take a molecule or cell type through clinical trials, regulatory approval, and commercialisation. And there are platform companies, organisations that own a core technology and licence it to developers, earning fees, milestones, and royalties without running programmes themselves. Alvion Bio is firmly in the second category.
We own Revalyxis™ - a proprietary system for sourcing, isolating, expanding, and supplying amniotic mesenchymal stem cells (AMSCs) to pharmaceutical and biotech companies worldwide. Our partners use those cells as the active ingredient in their clinical programmes. They take the development risk. We supply the superior raw material, licence our technology, and earn from every deal we sign.
The model is sometimes compared to Intel's original approach to the semiconductor industry: Intel did not build computers - they built the chip inside every computer, and earned a royalty each time. Alvion Bio does not build medicines. We supply the cell that goes inside them.
How we generate revenue
Four income streams from a single technology investment.
01 · Platform licensing
Pharmaceutical and biotech companies pay an upfront technology access fee to licence the Revalyxis™ platform for use in their development programmes. This is followed by development milestones - structured payments triggered as the partner's programme advances through preclinical and clinical stages.
02 · Application out-licensing
Where partners develop approved medicines using Revalyxis™ AMSCs, Alvion Bio earns royalties on commercial sales. These royalties are structured on a per-indication basis, meaning a partner developing therapies across multiple disease areas generates multiple independent royalty streams.
03 · Contract cell supply
Partners required a consistent and scalable supply of GMP-compatible AMSCs throughout their development. Alvion Bio supplies cells under long-term supply agreements, generating recurring revenue tied directly to partner programme activity.
04 · Strategic co-development
In select partnerships, Alvion Bio enters co-development arrangements, contributing cells and expertise in exchange for equity stakes or enhanced royalty rates. These selective partnerships offer the greatest commercial upside.
Why the model works
Lower risk. Multiple partners. Compounding returns.
No clinical trial exposure. Drug development is expensive, slow, and high-risk. Alvion Bio does not bear that risk. Our revenue is tied to partnership activity, not clinical outcomes, and our technology can be re-licenced if any single programme does not progress.
One investment, unlimited leverage. Unlike a pharmaceutical company that must invest in each new drug candidate, Alvion's technology base scales across partners and indications without requiring proportional reinvestment. Margins expand as deal volume grows.
Pharma prefers to buy rather than build. Internalising cell manufacturing is operationally complex. Most pharma companies choose to source cells externally. Alvion Bio is positioned as the preferred specialist supplier through demonstrable superiority.
Diversified revenue reduces concentration risk. Because we work with multiple partners, no single programme represents our entire exposure. Licence fees continue flowing even if one partner pauses. Supply revenue compounds alongside royalties.
The economics in practice
Early stage. A partner licences access and begins IND-enabling studies. Alvion receives upfront fees and begins supplying cells under a supply agreement. Development milestones are agreed for clinical events.
Growth stage. Supply volumes increase, milestones are triggered, and commercial relationships deepen. If partners expand into additional disease areas, the licence expands, adding new milestone and royalty schedules.
What a mature Alvion Bio partnership looks like.
Mature stage. At full maturity, an approved medicine triggers high-margin royalty flows requiring no incremental capital. Across multiple partnerships, these streams overlap creating a recurring and structurally scalable profile.
What we are not
Clarity on scope protects both sides of a partnership.
Alvion Bio does not conduct clinical trials or hold regulatory approvals for therapeutic use. We do not make prescribing claims or operate as a CRO. We supply superior cells and technology.
That division of roles is intentional and structural. It is the foundation of a model that can scale without the capital requirements or risk profile of vertically integrated pharmaceutical companies.
Building a cell therapy programme? Let's talk.
If you are developing clinical candidates and want access to the most biologically capable stem cell platform available, we would welcome a conversation.